ABC Arbitrage SA Makes New $1.16 Million Investment in Becton, Dickinson and Company $BDX

ABC Arbitrage SA acquired a new position in Becton, Dickinson and Company (NYSE:BDX) during the third quarter, Holdings Channel.com reports. The firm acquired 6,193 shares of the medical instruments supplier’s stock, valued at approximately $1,159,000.

Several other large investors also recently modified their holdings of the business. Gilbert & Cook Inc. grew its position in shares of Becton, Dickinson and Company by 2.0% during the second quarter. Gilbert & Cook Inc. now owns 2,844 shares of the medical instruments supplier’s stock worth $490,000 after buying an additional 56 shares in the last quarter. Mendel Money Management increased its position in Becton, Dickinson and Company by 2.6% in the second quarter. Mendel Money Management now owns 2,254 shares of the medical instruments supplier’s stock worth $388,000 after buying an additional 58 shares during the period. Focus Financial Network Inc. increased its holdings in shares of Becton, Dickinson and Company by 2.2% in the 3rd quarter. Focus Financial Network Inc. now owns 2,692 shares of the medical instruments supplier’s stock worth $504,000 after acquiring an additional 58 shares during the period. CX Institutional increased its stake in shares of Becton, Dickinson and Company by 3.6% in the third quarter. CX Institutional now owns 1,731 shares of the medical instruments supplier’s stock valued at $324,000 after purchasing an additional 60 shares during the period. Finally, Private Trust Co. NA raised its stake in Becton, Dickinson and Company by 1.6% during the 2nd quarter. Private Trust Co. NA now owns 3,927 shares of the medical instruments supplier’s stock valued at $676,000 after acquiring an additional 61 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Stock Performance

NYSE:BDX opened at $180.39 on Thursday. The firm’s 50-day moving average is $199.49 and its 200-day moving average is $192.35. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.64 and a current ratio of 1.05. The company has a market cap of $51.36 billion, a price-to-earnings ratio of 29.43, a PEG ratio of 1.90 and a beta of 0.25. Becton, Dickinson and Company has a 52-week low of $162.29 and a 52-week high of $235.34.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, topping the consensus estimate of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The company had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.15 billion. During the same quarter last year, the firm earned $3.43 EPS. Becton, Dickinson and Company’s revenue for the quarter was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be paid a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.3%. The ex-dividend date is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is currently 68.52%.

Becton, Dickinson and Company announced that its board has authorized a share buyback program on Tuesday, January 27th that allows the company to buyback $10.00 million in shares. This buyback authorization allows the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s board of directors believes its stock is undervalued.

Analyst Ratings Changes

BDX has been the topic of several recent analyst reports. Morgan Stanley boosted their target price on Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a report on Tuesday, December 2nd. Wall Street Zen lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Citigroup lowered their price target on Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating on the stock in a report on Tuesday. Wells Fargo & Company dropped their price objective on shares of Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating on the stock in a research note on Tuesday. Finally, Barclays started coverage on Becton, Dickinson and Company in a research note on Tuesday. They set an “overweight” rating and a $202.00 price target for the company. Five equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $196.00.

Trending Headlines about Becton, Dickinson and Company

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: BD closed its biosciences & diagnostics spin-off and merged that business with Waters, generating roughly $4 billion in proceeds and repositioning BD as a pure-play medical technology company — a strategic de‑risking that analysts and investors view favorably. BD Merges Biosciences & Diagnostics Business With Waters
• Positive Sentiment: Q1 FY2026: BD reported sales of ~$5.25B and EPS above consensus, and provided FY guidance — the beat + guidance underpin the bullish re-rating and help explain the intraday strength. BD (NYSE:BDX) Surprises With Q4 CY2025 Sales
• Positive Sentiment: High-profile endorsement: Jim Cramer publicly voiced support for the “new company” after the spin-off, which can boost retail interest and sentiment. Jim Cramer on Becton, Dickinson: “I kind of really like the new company”
• Positive Sentiment: BD launched cash tender offers to repurchase up to $1.6B of its outstanding debt, a move that can improve debt maturity profile and credit metrics. Investors often view targeted buybacks of debt as a constructive use of proceeds post‑spin. Becton Dickinson Launches $1.6 Billion Debt Tender Offers
• Neutral Sentiment: Analyst coverage and notes: Barclays initiated coverage with an Overweight and $202 PT (positive signal), while other firms adjusted targets — see items below; overall analyst activity is mixed and keeping volatility elevated. Barclays Overweight Note
• Neutral Sentiment: Earnings call transcript and post‑spin analysis provide more detail on margins, capital allocation and guidance assumptions for investors doing deeper due diligence. Q1 2026 earnings call transcript
• Negative Sentiment: Several high‑profile firms trimmed price targets or ratings: Wells Fargo cut its PT to $157 and moved to Equal Weight (notable downside from prior levels), and JPMorgan lowered its PT to $175 and maintained Neutral — these cuts add sell‑side caution. Analyst Target Changes (Wells Fargo / JPMorgan)
• Negative Sentiment: Other shops pared targets (RBC, Jefferies, Citi had updates); although many keep Buy/Overweight stances, the lower targets reflect uncertainty around near‑term margin recovery and the pace of capital deployment after the spin. Are Wall Street Analysts Bullish on Becton, Dickinson and Company Stock?

Insider Activity

In other news, EVP Michael David Garrison sold 1,610 shares of the firm’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the sale, the executive vice president owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. This trade represents a 11.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In the last ninety days, insiders have sold 2,463 shares of company stock worth $501,530. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.